What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patients will receive subcutaneous administration of MRG-001 at designated visits.”In the company’s words, NCT06307522 on ClinicalTrials.gov
- Tested for
- Alcoholic Hepatitis, Acute Alcoholic Hepatitis
- Main trialPhase 2
- “The goal of this study is to test MRG-001 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of MRG-001 in patients with severe alcoholic hepatitis (AH).”In the company’s words, NCT06307522 on ClinicalTrials.gov
Other drugs for Alcoholic Hepatitis
- LarsucosterolBausch Health Americas, Inc. · Durect · Phase 3
- TAK-242Yaqrit Ltd · Phase 2
- ALN-CIDEBRegeneron · Alnylam · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Sep 2026 | MRG-001 in Patients With Alcoholic Hepatitis | |
| Phase 2Unknown | 31 Mar 2022 | MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients | |
| Phase 2Completed | 1 Sep 2024 | Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients | |
| Phase 2Unknown | 1 Jan 2026 | MRG-001 in Patients With Amyotrophic Lateral Sclerosis | |
| Phase 2Unknown | 1 Feb 2026 | MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026